Schaefer, N G; Veit-Haibach, P; Soyka, J D; Steinert, H C; Stahel, R A (2012). Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): Value of 18F-FDG-PET/CT. European Journal of Radiology, 81(1):e19-e25.

von Boehmer, L; Draenert, A; Jungraithmayr, W; Inci, I; Niklaus, S; Boehler, A; Hofer, M; Stahel, R; Soltermann, A; van den Broek, M; Weder, W; Knuth, A (2012). Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. Lung Cancer, 76(1):118-122.

Scharl, Michael; Frei, Sandra; Pesch, Theresa; Kellermeier, Silvia; Arikkat, Joba; Frei, Pascal; Fried, Michael; Weber, Achim; Jehle, Ekkehard; Rühl, Anne; Rogler, Gerhard (2012). Interleukin-13 and transforming growth factor β synergise in the pathogenesis of human intestinal fistulae. Gut:Epub ahead of print.

Gridelli, Cesare; de Marinis, Filippo; Di Maio, Massimo; Ardizzoni, Andrea; Belani, Chandra P; Cappuzzo, Federico; Ciardiello, Fortunato; Fidias, Panagiotis; Paz-Ares, Luis; Perrone, Francesco; Pirker, Robert; De Petris, Luigi; Stahel, Rolf (2012). Maintenance treatment of advanced non-small-cell lung cancer: Results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Lung Cancer, 76(3):269-279.

Ziegler, A; Cerciello, F; Bigosch, C; Bausch-Fluck, D; Felley-Bosco, E; Ossola, R; Soltermann, A; Stahel, R A; Wollscheid, B (2012). Proteomic surfaceome analysis of mesothelioma. Lung Cancer, 75(2):189-196.

Brodowicz, T; Ciuleanu, T; Crawford, J; Filipits, M; Fischer, J R; Georgoulias, V; Gridelli, C; Hirsch, F R; Jassem, J; Kosmidis, P; Krzakowski, M; Manegold, C; Pujol, J L; Stahel, R; Thatcher, N; Vansteenkiste, J; Minichsdorfer, C; Zöchbauer-Müller, S; Pirker, R; Zielinski, C C (2012). Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Annals of Oncology, 23(5):1223-1229.

Pavlidis, N; Vermorken, J B; Stahel, R; Bernier, J; Cervantes, A; Pentheroudakis, G; Audisio, R A; Costa, A (2012). Undergraduate training in oncology: An ESO continuing challenge for medical students. Surgical Oncology, 21(1):15-21.

Sharma, A; Bode, B; Wenger, R H; Lehmann, K; Sartori, A A; Moch, H; Knuth, A; von Boehmer, L; van den Broek, M (2011). Gamma-radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE, 6(11):e28217.

Luehty, A; Stenner, F; Lohri, C; Muller, C; Samaras , P; Steiner, R; Van den Broek, M; Mischo, A; Renner, C; Knuth, A; Ruegg, C; Wenger, R H; Zweifel, M (2011). Autologous Stem Cell Transplantation: Leukapheresis Product has Anti-angiogenic Effects In Vivo Correlating with Neutrophil-derived VEGFR1. Anticancer Research, 31(10):3115-3124.

Hegi, M E; Diserens, A C; Bady, P; Kamoshima, Y; Kouwenhoven, M C; Delorenzi, M; Lambiv, WL; Hamou, M F; Matter, M S; Koch, A; Heppner, F L; Yonekawa, Y; Merlo, A; Frei, K; Mariani, L; Hofer, S (2011). Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib - a phase II trial. Molecular Cancer Therapeutics, 10(6):1102-1112.

Brokopp, C E; Schoenauer, R; Richards, P; Bauer, S; Lohmann, C; Emmert, M Y; Weber, B; Winnik, S; Aikawa, E; Graves, K; Genoni, M; Vogt, P; Luscher, T F; Renner, C; Hoerstrup, S P; Matter, C M (2011). Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. European Heart Journal, 32(21):2713-2722.

Stahel, R; Thatcher, N; Früh, M; Le Péchoux, C; Postmus, P E; Sorensen, J B; Felip, E (2011). 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Annals of Oncology, 22(9):1973-1980.

Lüthy, A. Auswirkungen der Autologen Stammzelltransplantation auf die Expression von VEGFR1 und die Angiogenese in vivo. 2011, University of Zurich, Faculty of Medicine.

Arbogast, S; Behnke, S; Opitz, I; Stahel, R A; Seifert, B; Weder, W; Moch, H; Soltermann, A (2011). Automated ERCC1 Immunohistochemistry in Non-small Cell Lung Cancer: Comparison of anti-ERCC1 Antibodies 8F1, D-10, and FL-297. Applied Immunohistochemistry & Molecular Morphology, 19(2):99-105.

Shi, Y; Hollenstein, A; Felley-Bosco, E; Fraefel, C; Ackermann, M; Soltermann, A; Weder, W; Stahel, R A; Pruschy, M; Opitz, I (2011). Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model. Lung Cancer, 71(3):370-371.

Pfreundschuh, M; Kuhnt, E; Trümper, L; Osterborg, A; Trneny, M; Shepherd, L; Gill, D S; Walewski, J; Pettengell, R; Jaeger, U; Zinzani, P L; Shpilberg, O; Kvaloy, S; de Nully Brown, P; Stahel, R; Milpied, N; López-Guillermo, A; Poeschel, V; Grass, S; Loeffler, M; Murawski, N (2011). CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncology, 12(11):1013-1022.

Vavricka, S R; Schoepfer, A M; Bansky, G; Binek, J; Felley, C; Geyer, M; Manz, M; Rogler, G; de Saussure, P; Sauter, B; Scharl, M; Seibold, F; Straumann, A; Michetti, P (2011). Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflammatory Bowel Diseases, 17(7):1530-1539.

Karbach , J; Neumann , A; Atmaca , A; Wahle , C; Brand , K; von Boehmer , L; Knuth , A; Bender , A; Ritter , G; Old , L J; Jäger , E (2011). Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clinical Cancer Research, 17(4):861-870.

Curioni-Fontecedro, A; Nuber , N; Mihic-Probst , D; Seifert , B; Soldini , D; Dummer , R; Knuth , A; van den Broek , M; Moch , H (2011). Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS ONE, 6(6):e21418.

Salazar, F; Molina, M A; Sanchez-Ronco, M; Moran, T; Ramirez, J L; Sanchez, J M; Stahel, R; Garrido, P; Cobo, M; Isla, D; Bertran-Alamillo, J; Massuti, B; Cardenal, F; Manegold, C; Lianes, P; Trigo, J M; Sanchez, J J; Taron, M; Rosell, R (2011). First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer, 72(1):84-91.

Pavlidis, N; Stahel, R; Hansen, H; Cervantes, A (2011). Fourteen years of evolution of ESMO Guidelines: from the minimum recommendations to the Consensus Conference-derived guidelines. Annals of Oncology, 22(Suppl 6):vi7-vi11.

Rettig, L; Seidenberg, S; Parvanova, I; Samaras, P; Knuth, A; Pascolo, S (2011). Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. International Journal of Cancer, 129(4):832-.838.

Sidi, R; Pasello, G; Opitz, I; Soltermann, A; Tutic, M; Rehrauer, H; Weder, W; Stahel, R A; Felley-Bosco, E (2011). Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. European Journal of Cancer, 47(2):326-332.

Knobel, P A; Kotov, I N; Felley-Bosco, E; Stahel, R A; Marti, T M (2011). Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia, 13(10):961-970.

Scharl, M; Leucht, K; Frey-Wagner, I; Zeitz, J; Hausmann, M; Fischbeck, A; Liebisch, G; Kellermeier, S; Pesch, T; Arikkat, J; Schmitz, G; Fried, M; Yildiz, Y; Rogler, G (2011). Knock-out of β-glucosidase 2 has no influence on dextran sulfate sodium-induced colitis. Digestion, 84(2):156-167.

von Boehmer, L; Keller, L; Mortezavi, A; Provenzano, M; Sais, G; Hermanns, T; Sulser, T; Jungbluth, A A; Old, L J; Kristiansen, G; van den Broek, M; Moch, H; Knuth, A; Wild, P J (2011). MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS ONE, 6(7):e21366.

Felip, E; Gridelli, C; Baas, P; Rosell, R; Stahel, R (2011). Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Annals of Oncology, 22(7):1507-1519.

Opitz, I; Erne, B V; Demirbas, S; Jetter, A; Seifert, B; Stahel, R; Weder, W (2011). Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study. Journal of Thoracic and Cardiovascular Surgery, 141(1):65-71.

Samaras, P; Blickenstorfer, M; Siciliano, R D; Haile, S R; Buset, E M; Petrausch, U; Mischo, A; Honegger, H; Schanz, U; Stüssi, G; Stahel, R A; Knuth, A; Stenner-Liewen, F; Renner, C (2011). Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Annals of Hematology, 90(1):89-94.

Frei, C; Opitz, I; Soltermann, A; Fischer, B; Moura, U; Rehrauer, H; Weder, W; Stahel, R; Felley-Bosco, E (2011). Pleural mesothelioma side populations have a precursor phenotype. Carcinogenesis, 32(9):1324-1332.

Scharl, M; Weber, A; Fürst, A; Farkas, S; Jehle, E; Pesch, T; Kellermeier, S; Fried, M; Rogler, G (2011). Potential role for snail family transcription factors in the etiology of Crohn's disease-associated fistulae. Inflammatory Bowel Diseases, 17(9):1907-1916.

Scharl, M; Wojtal, K A; Becker, H M; Fischbeck, A; Frei, P; Arikkat, J; Pesch, T; Kellermeier, S; Boone, D L; Weber, A; Loessner, M J; Vavricka, S R; Fried, M; McCole, D F; Rogler, G (2011). Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells. Inflammatory Bowel Diseases:Epub ahead of print.

Samaras, P; Breitenstein, S; Haile, S R; Stenner-Liewen, F; Heinrich, S; Feilchenfeldt, J; Renner, C; Knuth, A; Pestalozzi, B C; Clavien, P A (2011). Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Annals of Surgical Oncology, 18(7):1924-1931.

Vavricka, S R; Bentele, N; Scharl, M; Rogler, G; Zeitz, J; Frei, P; Straumann, A; Binek, J; Schoepfer, A M; Fried, M (2011). Systematic assessment of factors influencing preferences of crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflammatory Bowel Diseases:Epub ahead of print.

Zardavas , D; Meisel , A; Samaras , P; Knuth , A; Renner , C; Pestalozzi , B C; Stenner-Liewen , F (2011). Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. Case Reports in Oncology, 4(1):16-18.

Weder, W; Stahel, R A; Baas, P; Dafni, U; de Perrot, M; McCaughan, B C; Nakano, T; Pass, H I; Robinson, B W S; Rusch, V W; Sugarbaker, D J; van Zandwijk, N (2011). The MARS feasibility trial: conclusions not supported by data. Lancet Oncology, 12(12):1093-1094; author reply 1094.

Parvanova , I; Rettig , L; Knuth, A; Pascolo, S (2011). The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. Vaccine, 29(22):3832-3836.

Knobel, P A; Marti, T M (2011). Translesion DNA synthesis in the context of cancer research. Cancer Cell International, 11:39.

Gridelli, C; Stahel, R; Besse, B; Ciardiello, F; Felip, E; Gasparini, S; Graziano, P; Rossi, A; de Marinis, F (2011). Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer, 74(3):544-548.

Samaras, P; Blickenstorfer, M; Haile, S R; Siciliano, D; Petrausch, U; Mischo, A; Zweifel, M; Honegger, H; Schanz, U; Stüssi, G; Taverna, C; Bauer, S; Knuth, A; Stenner-Liewen, F; Renner, C (2011). Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. Swiss Medical Weekly, 141:w13203.

Frauenfelder, T; Tutic, M; Weder, W; Götti, R P; Stahel, R A; Seifert, B; Opitz, I (2011). Volumetry - an alternative to assess therapy response for malignant pleural mesothelioma? European Respiratory Journal, 38(1):162-168.

Imig, J; Motsch, N; Zhu, J Y; Barth, S; Okoniewski, M; Reineke, T; Tinguely, M; Faggioni, A; Trivedi, P; Meister, G; Renner, C; Grässer, F A (2011). microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Research, 39(5):1880-.1893.

Sharma, A; Bode, B; Wenger, R H; Lehmann, K; Sartori, A A; Moch, H; Knuth, A; von Boehmer, L; van den Broek, M (2011). γ-radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE, 6(11):e28217.

Craig, V J; Arnold, I; Gerke, C; Huynh, M Q; Wundisch, T; Neubauer, A; Renner, C; Falkow, S; Mueller, A (2010). Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood, 115(3):581-591.

Burckhart, T; Thiel, M A; Nishikawa, H; Wüest, T; Müller, D; Zippelius, A; Ritter, G; Old, L; Shiku, H; Renner, C (2010). Tumor-specific crosslinking of GITR as costimulation for immunotherapy. Journal of Immunotherapy, 33(9):925-934.

Scherpereel, A; Astoul, P; Baas, P; Berghmans, T; Clayson, H; de Vuyst, P; Dienemann, H; Galateau-Salle, F; Hennequin, C; Hillerdal, G; Le Pe'choux, C; Mutti, L; Pairon, J C; Stahel, R; van Houtte, P; van Meerbeeck, J; Waller, D; Weder, W (2010). Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 13(10):C23-C45.

Giger, O; Caduff, R; O'Meara, A; Diener, P A; Knuth, A; Jäger, D; Moch, H; Varga, Z (2010). Frequent expression of the breast differentiation antigen NY-BR-1 in mammary and extramammary Paget's disease. Pathology international, 60(11):726-734.

Speiser, D E; Schwarz, K; Baumgaertner, P; Conzett, K B; Manolova, V; Devevre, E; Sterry, W; Walden, P; Zippelius, A; Senti, G; Voelter, V; Cerottini, J P; Guggisberg, D; Willers, J; Geldhof, C; Romero, P; Kündig, T; Knuth, A; Dummer, R; Trefzer, U; Bachmann, M F (2010). Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of Immunotherapy, 33(8):848-858.

Garbi, N; Hämmerling, G J; Probst, H C; van den Broek, M (2010). Tonic T cell signalling and T cell tolerance as opposite effects of self-recognition on dendritic cells. Current Opinion in Immunology, 22(5):601-608.

Fischer, E; Kobold, S; Kleber, S; Kubuschok, B; Braziulis, E; Knuth, A; Renner, C; Wadle, A (2010). Cryptic epitopes induce high-titer humoral immune response in patients with cancer. Journal of Immunology, 85(5):3095-3102.

Nuber, N; Curioni-Fontecedro, A; Matter, C; Soldini, D; Tiercy, J M; von Boehmer, L; Moch, H; Dummer, R; Knuth, A; van den Broek, M (2010). Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 107(34):15187-15192.

Petrausch, U; Samaras, P; Haile, S R; Veit-Haibach, P; Soyka, J D; Knuth, A; Hany, T F; Mischo, A; Renner, C; Schäefer, N G (2010). Risk adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first line therapy. Annals of Oncology, 21(8):1694-1698.

Walter, A; Barysch, MJ; Behnke, S; Dziunycz, P; Schmid, B; Ritter, E; Gnjatic, S; Kristiansen, G; Moch, H; Knuth, A; Dummer, R; van den Broek , M (2010). Cancer Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas. Clinical Cancer Research, 16(14):3562-3570.

Pavlidis, N; Hansen, H; Stahel, R (2010). ESMO Clinical Practice Guidelines: development, implementation and dissemination. Annals of Oncology, 21(Suppl ):v7-v8.

Stahel, R A; Weder, W; Lievens, Y; Felip, E (2010). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21(Suppl ):v126-v128.

Goetti, R; Leschka, S; Desbiolles, L; Klotz, E; Samaras, P; von Boehmer, L; Stenner, F; Reiner, C; Stolzmann, P; Scheffel, H; Knuth, A; Marincek, B; Alkadhi, H (2010). Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases. Investigative Radiology, 45(7):419-426.

Rettig, L; Haen, S P; Bittermann, A G; von Boehmer, L; Curioni, A; Krämer, S D; Knuth, A; Pascolo, S (2010). Particle size and activation threshold: a new dimension of danger signaling. Blood, 115(22):4533-4541.

Weder, W; Collaud, S; Eberhardt, W E E; Hillinger, S; Welter, S; Stahel, R; Stamatis, G (2010). Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 139(6):1424-1430.

Petrausch, U; Samaras, P; Veit-Haibach, P; Tschopp, A; Soyka, J D; Knuth, A; Hany, T F; Mischo, A; Renner, C; Schaefer, N G (2010). Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Annals of Oncology, 21(5):1053-1057.

Ospelt, C; Mertens, J C; Jüngel, A; Brentano, F; Maciejewska-Rodriguez, H; Huber, L C; Hemmatazad, H; Wüest, T; Knuth, A; Gay, R E; Michel, B A; Gay, S; Renner, C; Bauer, S (2010). Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism, 62(5):1224-1235.

Stahel, R; Baas, P; Faivre-Finn, C; Dooms, C; Passlick, B; Mazières, J; Cappuzzo, F; Früh, M; Sorensen, J B; Blackhall, F; Taron, M; Gridelli, C; O'Byrne, K; Rosell, R (2010). Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). Lung Cancer, 68(1):121-124.

Samaras, P; Heider, H; Haile, S R; Petrausch, U; Schaefer, N G; Siciliano, R D; Meisel, A; Mischo, A; Zweifel, M; Knuth, A; Stenner-Liewen, F; Renner, C (2010). Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Annals of Hematology, 89(8):783-787.

Veit-Haibach, P; Schaefer, N G; Steinert, H C; Soyka, J D; Seifert, B; Stahel, R A (2010). Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer, 67(3):311-317.

Jung, V; Fischer, E; Imig, J; Kleber, S; Nuber, N; Reinshagen, F; Kamradt, J; Grobholz, R; Knuth, A; Renner, C; Wadle, A (2010). Yeast-based identification of prostate tumor antigens provides an effective vaccine platform. Anticancer Research, 30(3):895-902.

Stiefel, F; Barth, J; Bensing, J; Fallowfield, L; Jost, L; Razavi, D; Kiss, A (2010). Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009. Annals of Oncology, 21(2):204-207.

Zweifel, M; Stenner-Liewen, F; Weber, A; Samaras, P; Zaugg, K; Knuth, A; Soyka, J D (2010). Increased bone marrow activity on F-18-FDG PET/CT in granulocyte colony stimulating factor producing anaplastic thyroid carcinoma. Clinical Nuclear Medicine, 35(2):103-104.

Power, D G; Feilchenfeldt, J (2010). Irinotecan and mismatch repair deficiency. Annals of Oncology, 21(2):432-433.

Schildknecht, A; Brauer, S; Brenner, C; Lahl, K; Schild, H; Sparwasser, T; Probst, H C; van den Broek, M (2010). FoxP3+ regulatory T cells essentially contribute to peripheral CD8+ T-cell tolerance induced by steady-state dendritic cells. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 107(1):199-203.

Reck, M; Stahel, R A; von Pawel, J; Karthaus, M; Korfee, S; Serke, M; Schuette, W H W; Eschbach, C; Fink, T H; Leschinger, M I; Manegold, C (2010). Pemetrexed in the treatment of malignant mesothelioma: Results from an expanded access program in Germany. Respiratory Medicine, 104(1):142-148.

Pirker, R; Herth, F J F; Kerr, K M; Filipits, M; Taron, M; Gandara, D; Hirsch, F R; Grunenwald, D; Popper, H; Smit, E; Dietel, M; Marchetti, A; Manegold, C; Schirmacher, P; Thomas, M; Rosell, R; Cappuzzo, F; Stahel, R (2010). Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. Journal of Thoracic Oncology, 5(10):1706-1713.

Flatz, L; Hegazy, A N; Bergthaler, A; Verschoor, A; Claus, C; Fernandez-Rivas, M; Gattinoni, L; Johnson, S; Kreppel, F; Kochanek, S; Broek, M; Radbruch, A; Lévy, F; Lambert, P H; Siegrist, C A; Restifo, N P; Löhning, M; Ochsenbein, A F; Nabel, G J; Pinschewer, D D (2010). Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nature Medicine, 16(3):339-345.

van den Broek, M; von Boehmer, L; Knuth, A (2010). Developments in cancer immunotherapy. Digestive Diseases, 28(1):51-6.

Thiel, M; Wolfs, M J; Bauer, S; Wenning, A S; Burckhart, T; Schwarz, E C; Scott, A M; Renner, C; Hoth, M (2010). Efficiency of T-cell costimulation by CD80 and CD86 cross-linking correlates with calcium entry. Immunology, 129(1):28-40.

Samaras, P; Buset, E M; Siciliano, R D; Haile, S R; Petrausch, U; Mischo, A; Honegger, H; Pestalozzi, B C; Schanz, U; Stüssi, G; Stahel, R A; Knuth, A; Renner, C; Stenner-Liewen, F (2010). Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. Oncology, 79(1-2):93-97.

Müller, C. Expression von löslischem und transmembranärem VEGF Rezeptor 1 in Brustkrebs- und Endothelzellen unter Hypoxie und Normoxie. 2010, University of Zurich, Faculty of Medicine.

Maciejewska-Rodrigues, H; Al-Shamisi, M; Hemmatazad, H; Ospelt, C; Bouton, M C; Jäger, D; Cope, A P; Charles, P; Plant, D; Distler, J H W; Gay, R E; Michel, B A; Knuth, A; Neidhart, M; Gay, S; Jüngel, A (2010). Functional autoantibodies against serpin E2 in rheumatoid arthritis. Arthritis and Rheumatism, 62(1):93-104.

Moebius, J; van den Broek, M; Groettrup, M; Basler, M (2010). Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. European Journal of Immunology, 40(12):3439-3449.

Peralta, R; Baudis, M; Vazquez, G; Juárez, S; Ortiz, R; Decanini, H; Hernandez, D; Gallegos, F; Valdivia, A; Piña, P; Salcedo, M (2010). Increased expression of cellular retinol-binding protein 1 in laryngeal squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 136(6):931-938.

Martinelli, G; Schmitz, S F H; Utiger, U; Cerny, T; Hess, U; Bassi, S; Okkinga, E; Stupp, R; Stahel, R; Heizmann, M; Vorobiof, D; Lohri, A; Dietrich, P Y; Zucca, E; Ghielmini, M (2010). Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. Journal of Clinical Oncology, 28(29):4480-4484.

Wadle, A; Mischo, A; Strahl, S; Nishikawa, H; Held, G; Neumann, F; Wullner, B; Fischer, E; Kleber, S; Karbach, J; Jager, E; Shiku, H; Odunsi, K; Shrikant, P A; Knuth, A; Cerundolo, V; Renner, C (2010). NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. FEMS Yeast Research, 27(11):919-931.

Pavlidis, N; Gatzemeier, W; Popescu, R; Stahel, R; Pinedo, H; Cavalli, F; Costa, A (2010). The masterclass of the european school of oncology: the 'key educational event' of the school. European Journal of Cancer, 46(12):2159-2165.

Renner, C; Zippelius, A; Riethmüller, G; Knuth, A (2010). Tumorimmunologie. In: Hiddemann, W; Bartram, C R. Die Onkologie. Berlin, Deutschland, 325-345. ISBN 978-3-540-79724-1.

Stupp, R; Mayer, M; Kann, R; Weder, W; Zouhair, A; Betticher, D C; Roth, A D; Stahel, R A; Majno, S; Peters, S; Jost, L; Furrer, M; Thierstein, S; Schmid, R A; Hsu-Schmitz, S F; Mirimanoff, R O; Ris, H B; Pless, M (2009). Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncology, 10(8):785-793.

Bauer, S; Oosterwijk-Wakka, J C; Adrian, N; Oosterwijk, E; Fischer, E; Wüest, T; Stenner, F; Perani, A; Cohen, L S; Knuth, A; Divgi, C; Jäger, D; Scott, A M; Ritter, G; Old, L J; Renner, C (2009). Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. International Journal of Cancer, 125(1):115-123.

Schildknecht, A; Probst, H C; McCoy, K D; Miescher, I; Brenner, C; Dino, P; Leone, D; Suter, U; Ohashi, P S; van den Broek, M (2009). Antigens expressed by myelinating glia cells induce peripheral cross-tolerance of endogenous CD8+ T cells. European Journal of Immunology, 36(6):1505-1515.

Pavlidis, N; Hansen, H; Stahel, R (2009). ESMO clinical recommendations: using the easier and faster approach to oncology guidelines. Annals of Oncology, 20 Sup:7-9.

Thurneysen, C; Opitz, I; Kurtz, S; Weder, W; Stahel, R A; Felley-Bosco, E (2009). Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer, 64(2):140-147.

Carteni, G; Manegold, C; Martin Garcia, G; Siena, S; Zielinski, C C; Amadori, D; Liu, Y; Blatter, J; Visseren-Grul, C; Stahel, R (2009). Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer, 64(2):211-218.

Stewart-Jones, G; Wadle, A; Hombach, A; Shenderov, E; Held, G; Fischer, E; Kleber, S; Stenner-Liewen, F; Bauer, S; McMichael, A; Knuth, A; Abken, H; Hombach, A A; Cerundolo, V; Jones, E Y; Renner, C (2009). Rational development of high-affinity T-cell receptor-like antibodies. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 106(14):5784-5788.

Bauer, S; Adrian, N; Siebenborn, U; Fadle, N; Plesko, M; Fischer, E; Wüest, T; Stenner, F; Mertens, J C; Knuth, A; Ritter, G; Old, L J; Renner, C (2009). Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. Cancer Immunity, 9(2):1-10.

Knights, A J; Nuber, N; Thomson, C W; de la Rosa, O; Jäger, E; Tiercy, J M; van den Broek, M; Pascolo, S; Knuth, A; Zippelius, A (2009). Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunology, Immunotherapy, 58(3):325-338.

Atmaca, A; Al-Batran, S E; Neumann, A; Kolassa, Y; Jäger, D; Knuth, A; Jäger, E (2009). Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - A phase II study. Gynecologic oncology, 112(2):384-388.

Riener, M O; Stenner, F; Liewen, H; Soll, C; Breitenstein, S; Pestalozzi, B C; Samaras, P; Probst-Hensch, N M; Hellerbrand, C; Müllhaupt, B; Clavien, P A; Bahra, M; Neuhaus, P; Wild, P; Fritzsche, F; Moch, H; Jochum, W; Kristiansen, G (2009). Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology, 49(5):1602 -1609.

Ampollini, L; Soltermann, A; Felley-Bosco, E; Lardinois, D; Arni, S; Speck, R F; Weder, W; Opitz, I (2009). Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting. European Journal of Cardio-Thoracic Surgery, 35(3):457-462.

Riener, M O; Wild, P J; Soll, C; Knuth, A; Jin, B; Jungbluth, A; Hellerbrand, C; Clavien, P A; Moch, H; Jochum, W (2009). Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. International Journal of Cancer, 124(2):352-357.

Scherpereel, A; Astoul, P; Baas, P; Berghmans, T; Clayson, H; de Vuyst, P; Dienemann, H; Galateau-Salle, F; Hennequin, C; Hillerdal, G; Le Péchoux, C; Mutti, L; Pairon, J C; Stahel, R; van Houtte, P; van Meerbeeck, J; Waller, D; Weder, W (2009). Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of Malignant Pleural Mesothelioma. European Respiratory Journal:Epub ahead of print.

Stahel, R A; Weder, W (2009). Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach? Current Opinion in Oncology, 21(2):124-130.

Stahel, R A; Felley-Bosco, E; Opitz, I; Weder, W (2009). Malignant pleural mesothelioma. Future Oncology, 5(3):391-402.

Stahel, R A; Weder, W; Felip, E (2009). Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 20 Sup:73-75.

Weder, W; Opitz, I; Stahel, R (2009). Multimodality strategies in malignant pleural mesothelioma. Seminars in Thoracic and Cardiovascular Surgery, 21(2):172-176.

Keller, A M; Schildknecht , A; Xiao , Y; van den Broek , M; Borst, J (2008). Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity, 29(6):934-946.

Carralot , J P; Lemmel, C; Stevanovic , S; Pascolo , S (2008). Mass spectrometric identification of an HLA-A*0201 epitope from Plasmodium falciparum MSP-1. International Immunology, 20(11):1451-1456.

Pestalozzi, B C; e al,; Gelber, R D; Viale, G (2008). Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Annals of Oncology, 19(11):1837-1841.

Held, G; Neumann, F; Sturm, C; Kaestner, L; Dauth, N; de Bruijn, D R; Renner, C; Lipp, P; Pfreundschuh, M (2008). Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells. International Journal of Cancer, 123(8):1841-1847.

Audisio, C; Stahel, V; Aapro, M S; Costa, A; Pandey, M; Pavlidis, N (2008). Successful publishing: How to get your paper accepted. Surgical Oncology, 18(4):350-356.

Stahel, R; Felley-Bosco, E; Opitz, I; Weder, W (2008). Mesothelioma. In: Hansen, H. Lung Cancer Therapy Annual 6. New York, 205-222.

Ribi, K; Bernhard, J; Schuller, J C; Weder, W; Bodis, S; Jörger, M; Betticher, D; Schmid, R A; Stupp, R; Ris, H B; Stahel, R A (2008). Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung Cancer, 61(3):398-404.

Stahel, R A (2008). Educational book of the 33rd ESMO Congress Stockholm, Sweden 12-16 September 2008. Introduction. Annals of Oncology, 19 Sup:vii22.

Mangana, J; Zipser, M C; Conrad, C; Oberholzer, P A; Cozzio, A; Knuth, A; French, L E; Dummer, R (2008). Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. European Journal of Dermatology, 18(5):566-570.

Stenner, F; Liewen, H; Zweifel, M; Weber, A; Tchinda, J; Bode, B; Samaras, P; Bauer, S; Knuth, A; Renner, C (2008). Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Science, 99(9):1847-1852.

Bernhard , J; Dietrich , D; Scheithauer , W; Gerber , D; Bodoky , G; Ruhstaller , T; Glimelius , B; Bajetta , E; Schüller , J; Saletti , P; Bauer , J; Figer , A; Pestalozzi , B C; Köhne , C H; Mingrone, W; Stemmer , S M; Tàmas , K; Kornek , G V; Koeberle, D; Herrmann , R (2008). Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001. Journal of Clinical Oncology, 26(22):3695-3701.

Gruber, G; Cole, B F; Castiglione-Gertsch, M; Stahel, R A (2008). Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Annals of Oncology, 19(8):1393-1401.

Borner , M; Koeberle , D; Von Moos , R; Saletti , P; Rauch , D; Hess , V; Trojan , A; Helbling , D; Pestalozzi , B; Caspar, C; Ruhstaller , T; Roth , A; Kappeler , A; Dietrich, D; Lanz , D; Mingrone , W (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the swiss group for clinical cancer research SAKK. Annals of Oncology, 19(7):1288 -1292 .

Santoro, A; O'Brien, M E; Stahel, R A; Nackaerts, K; Baas, P; Karthaus, M; Eberhardt, W; Paz-Ares, L; Sundstrom, S; Liu, Y; Ripoche, V; Blatter, J; Visseren-Grul, C M; Manegold, C (2008). Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. Journal of Thoracic Oncology, 3(7):756-763.

Shebzukhov, Y V; Lavrik, I N; Karbach, J; Khlgatian, S V; Koroleva, B P; Belousov, P V; Kashkin, K N; Knuth, A; Jager, E; Chi, N W; Kuprash, D V; Nedospasov, S A (2008). Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients. Cancer Immunology, Immunotherapy, 57(6):871-881.

Rosell, R; Manegold, C; Moran, T; Garrido, P; Blanco, R; Lianes, P; Stahel, R; Trigo, JM; Wei, J; Taron, M (2008). Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 9(Supplement 2):S76-S82.

Schwab, M; Zanger, U M; Marx, C; Schaeffeler, E; Klein, K; Dippon, J; Kerb, R; Blievernicht, J; Fischer, J; Hofmann, U; Bokemeyer, C; Eichelbaum, M (2008). Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. Journal of Clinical Oncology, 26(13):2131-2138.

Waibel, R; Treichler, H; Schaefer, N G; van Staveren, D R; Mundwiler, S; Kunze, S; Küenzi, M; Alberto, R; Nüesch, J; Knuth, A; Moch, H; Schibli, R; Schubiger, P A (2008). New derivatives of vitamin B12 show preferential targeting of tumors. Cancer Research, 68(8):2904-2911.

Tinguely, M; Jenni, B; Knights, A; Lopes, B; Korol, D; Rousson , V; Curioni Fontecedro, A; Cogliatti, S B; Bittermann, A G; Schmid, U; Dommann-Scherrer, C; Maurer, R; Renner, C; Probst-Hensch, N M; Moch, H; Knuth, A; Zippelius, A (2008). MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Science, 99(4):720-725.

Viale, G; Regan, M M; Maiorano, E; Stahel, R A (2008). Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Journal of Clinical Oncology, 26(9):1404-1410.

Al-Batran, S E; Hartmann, J T; Probst, S; Schmalenberg, H; Hollerbach, S; Hofheinz, R; Rethwisch, V; Seipelt, G; Homann, N; Wilhelm, G; Schuch, G; Stoehlmacher, J; Derigs, H G; Hegewisch-Becker, S; Grossmann, J; Pauligk, C; Atmaca, A; Bokemeyer, C; Knuth, A; Jäger, E (2008). Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology, 26(9):1435-1442.

Curioni-Fontecedro, A; Knights, A J; Tinguely, M; Nuber, N; Schneider, C; Thomson, C W; von Boehmer, I; Bossart, W; Pahlich, S; Gehring, H; Moch, H; Renner, C; Knuth, A; Zippelius, A (2008). MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia, 22(8):1646-1648.

Schildknecht, A; Welti, S; Geuking, M B; Hangartner, L; van den Broek, M (2008). Absence of CTL responses to early viral antigens facilitates viral persistence. Journal of Immunology, 180(5):3113-3121.

Weide, B; Carralot, J P; Reese, A; Scheel, B; Eigentler, T K; Hoerr, I; Rammensee, H G; Garbe, C; Pascolo, S (2008). Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. Journal of Immunotherapy, 31(2):180-188.

Weide, B; Garbe, C; Rammensee , H G; Pascolo, S (2008). Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunology Letters, 115(1):33-42.

Theurillat, J P; Zürrer-Härdi, U; Varga, Z; Barghorn, A; Saller, E; Frei, C; Storz, M; Behnke, S; Seifert, B; Fehr, M; Fink, D; Rageth, C; Linsenmeier, C; Pestalozzi, B; Chen, Y T; Knuth, A; Jäger, D; Moch, H (2008). Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. International Journal of Cancer, 122(7):1585-1591.

Samaras, P; Pfammatter, T; Pestalozzi, B C (2008). Hemorrhage associated with hepatic artery pseudoaneurysms after regional chemotherapy with floxuridine: case report. International Seminars in Surgical Oncology, 5:17:1-5.

Pentheroudakis, G; Stahel, R; Hansen, H; Pavlidis, N (2008). Heterogeneity in cancer guidelines: should we eradicate or tolerate? Annals of Oncology, 19(12):2067-2078.

Stahel, R A; Weder, W; Felip, E (2008). Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 19(Suppl ):ii43-ii44.

D'Addario, G; Rauch, D; Stupp, R; Pless, M; Stahel, R; Mach, N; Jost, L; Widmer, L; Tapia, C; Bihl, M; Mayer, M; Ribi, K; Lerch, S; Bubendorf, L; Betticher, D C (2008). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of Oncology, 19(4):739-745.

Opitz, I; Soltermann, A; Abaecherli, M; Hinterberger, M; Probst-Hensch, N; Stahel, R; Moch, H; Weder, W (2008). PTEN expression is a strong predictor of survival in mesothelioma patients. European Journal of Cardio-Thoracic Surgery, 33(3):502-506.

Diezi, J; Felley-Bosco, E. Precis de toxicologie. Genève, 2008. ISBN 978-2-88049-259-5.

Regan, M M; Pagani, O; Walley, B; et al,; Stahel, R A (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Annals of Oncology, 19(7):1231-1241.

Viale, G; Giobbie-Hurder, A; Regan, M M; Stahel, R A (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. Journal of Clinical Oncology, 26(34):5569-5575.

Heinrich, S; Pestalozzi, B C; Schäfer, M; Weber, A; Bauerfeind, P; Knuth, A; Clavien, P A (2008). Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology, 26(15):2526-2531.

Belyanskaya, L L; Ziogas, A; Hopkins-Donaldson, S; Kurtz, S; Simon, H U; Stahel, R; Zangemeister-Wittke, U (2008). TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer, 60(3):355-365.

Ravaioli, A; Monti, F; Regan, M M; Maffini, F; Mastropasqua, M G; Spataro, V; Castiglione-Gertsch, M; Panzini, I; Gianni, L; Goldhirsch, A; Coates, A; Price, K N; Gusterson, B A; Viale, G (2008). p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Annals of Oncology, 19(4):660-668.

von Minckwitz, G; Harder, S; Hövelmann, S; Jäger, E; Al-Batran, S E; Loibl, S G; Atmaca, A; Cimpoiasu, C; Neumann, A M; Abera, A; Knuth, A L; Kaufmann, M; Jäger, D; Maurer, A B; Wels, W S (2005). Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Research, 7(5):R617-R626.